Ireland
--:--IST
Latest
Clinical Trials in France / NCT05794646
Active, not recruiting Not applicable

Community Intervention to Eliminate HCV Among People Who Use Drugs.

NCT05794646 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-10-02
Last updated
2025-09-08

Condition(s) studied

HCVSubstance Use Disorders

Investigational drug(s) / intervention(s)

Hybrid effectiveness-implementation study type 2

Hybrid effectiveness-implementation study type 2: Diagnosis of hepatitis C; Assessment of hepatic fibrosis; Treatment of hepatitis C; Assessment of psychological disorders and treatment or referral.

Study summary

The goal of this interventional study is twofold with the evaluation of the feasibility and potential usefulness of an implementation strategy, and the efficiency of a community-based model of mass screening and immediate treatment of hepatitis C among People Who Use Drugs (PWUD) in three major cities in mainland France (Paris, Lyon and Marseille) and in one overseas city (Fort-de-France). The investigators will also describe the psychological and infectious comorbidities of drug users, determine the stages of the HCV (Hepatitis C Virus), HBV (Hepatitis B Virus), HIV (Human Immunodeficiency Virus) care cascade, and analyze the factors associated with HCV treatment failure. A qualitative study will investigate the acceptability of the RDS model.

Participants will be screened in an out of bound research center and receive appropriate treatment for infectious, addictological and psychiatric troubles. They will receive coupons to give to their peers for them to participate in the study.

Researchers will also compare the acceptability of referral to psychiatric care directly at the research site (intervention group) with that of referral directly to a city facility (control group).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion criteria: * Age \> 18 years; * Person who uses drugs, defined as: * Reported psychoactive substance use and * Positive urine test for at least one of the following: heroin, amphetamines, cocaine, MDMA (methylenedioxymethamphetamine), ecstasy, or misused opioid medications (methadone, buprenorphine or opiates used for a reason other than its original prescription (effects seeking) or used in a way that does not comply with its marketing authorisation (injected, snorted, taken multiple times beyond the prescribed dosage)) ; * Informed and signed consent Exclusion criteria: * Inability to understand the study; * Being under guardianship, curatorship or mandate of future protection; * Person participating in another research study with an exclusion period still in progress at the time of pre-inclusion.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Lyon Lyon Auvergne-Rhône-Alpes
Marseille Marseille PACA
Paris Paris Île-de-France Region
Martinique Fort-de-France Martinique

More ANRS, Emerging Infectious Diseases trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05794646 on ClinicalTrials.gov ↗ ← All trials in France